Journal
CELLULAR & MOLECULAR IMMUNOLOGY
Volume 16, Issue 1, Pages 40-52Publisher
CHIN SOCIETY IMMUNOLOGY
DOI: 10.1038/s41423-018-0168-y
Keywords
PVR; tumor; immunotherapy; checkpoint; TIGIT; poliovirus
Categories
Funding
- grant Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology [KK.01.1.1.01.0006]
- Croatian Science Foundation (HRZZ) [1533]
- European Regional Development Fund
Ask authors/readers for more resources
Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available